/ny_teaser_oct_08.gif)
Allergy Vaccine Tablet GRAZAX® Honoured as Product of the Year
ALK's tablet-based vaccine against grass allergy, GRAZAX®, has been awarded "Product of the Year" by The Confederation of Danish Industry
ALK's tablet-based vaccine against grass allergy, GRAZAX®, has been awarded "Product of the Year" by The Confederation of Danish Industry. GRAZAX® is the first allergy tablet to treat the underlying cause of the allergic disease as well as the symptoms.
- By developing GRAZAX®, ALK has made an innovative breakthrough, that will pave the way for new tablet-based allergy vaccines, said Jesper Møller, chairman of The Confederation of Danish Industry, when presenting the award.
GRAZAX® was launched in Europe in 2007 following a pan-European marketing authorization. Contrary to traditional, symptom-relieving allergy medicine, GRAZAX® treats the actual cause of the allergic disease, and the treatment is administered as a once-daily, fast dissolving tablet. Before the introduction of GRAZAX®, such a registered causal allergy treatment was only available as an injection-based treatment requiring 30-40 visits at specialised allergy clinics.
Read the full press release.
